Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Chen Y, Zhang L, Shi X, Han J, Chen J, Zhang X, et al. Characterization of the Nucleus Pulposus Progenitor Cells via Spatial Transcriptomics. Adv Sci (Weinh). 2024:e2303752.

Li J, Chin CR, Ying H-, Meydan C, Teater MR, Xia M, et al. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun. 2024;15(1):2879.

Lee-Saxton YJ, Egan CE, Bratton BA, Thiesmeyer JW, Greenberg JA, Marshall TE, et al. Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence. J Clin Endocrinol Metab. 2024.

VandenBussche CJ, Nwosu A, Souers R, Sundling KE, Brainard J, Goyal A, et al. The Implementation of Nongynecologic Reporting Systems in Cytopathology Laboratories Is Highly Variable: Analysis of Data From a 2020 Supplemental Survey of Participants in the College of American Pathologists Interlaboratory Comparison Program in . Arch Pathol Lab Med. 2024;148(5):531-537.

Kirmaier A, Kubiak J, Mahler L, Qian X, Wu L, Ono Y, et al. Case report and mini-review: Sarcina ventriculi in the stomach of an 80-year-old female. Diagn Microbiol Infect Dis. 2024;108(2):116137.

Myint O, Sakunrangsit N, Pholtaisong J, Toejing P, Pho-On P, Leelahavanichkul A, et al. Differential Gene Expression Involved in Bone Turnover of Mice Expressing Constitutively Active TGFβ Receptor Type I. Int J Mol Sci. 2024;25(11).

Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024;584:216608.

Hu S, Graham RP, Choi W-, Wen KW, Putra J, Chen W, et al. Clinicopathologic Features of Gastrointestinal Tract Langerhans Cell Histiocytosis. Mod Pathol. 2024;37(9):100543.

Venkadakrishnan VB, Presser AG, Singh R, Booker MA, Traphagen NA, Weng K, et al. Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes. Res Sq. 2024.

Hoellwarth JS, Reif TJ, Mori S, Kang R, Magro CM. Horrifying Basal Cell Carcinoma Presenting as Progressive Pyoderma Gangrenosum: Case Report. Case Rep Oncol. 2024;17(1):298-304.